Boston advertises commitment to ensuring defibrillator quality:
This article was originally published in Clinica
Executive Summary
Boston Scientific ran an open letter to customers and patients in US newspaper advertisements last week reassuring them about its commitment to achieving "world-class quality" for its Guidant-acquired line of defibrillators and "clear leadership" in this field. In the letter, company president and CEO James Tobin said he had taken personal responsibility for overseeing the company's defibrillator division and has put a new management team in place. "We are focused on the highest standards of innovation, quality and reliability," he said. "And we have made timely, transparent and responsible communication a requirement."
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.